The shares of Horizon Technology Finance Corporation (NASDAQ:HRZN) has been pegged with a rating of Buy by Aegis Capital in its latest research note that was published on March 04, 2020. The Financial company has also assigned a $13.20 price target. Aegis Capital wasn’t the only research firm that published a report of Horizon Technology Finance Corporation, with other equities research analysts also giving their opinion on the stock. Compass Point advised investors in its research note published on February 28, 2020, to Neutral the HRZN stock while also putting a $10.50 price target. The stock had earned Neutral rating from B. Riley FBR Markets when it published its report on February 04, 2020. That day the B. Riley FBR set price target on the stock to $12. The stock was given Hold rating by Aegis Capital in its report released on January 06, 2020, the day when the price target on the stock was placed at 13.10. Janney was of a view that HRZN is Neutral in its latest report on October 29, 2019. Wells Fargo thinks that HRZN is worth Underperform rating.
The price of the stock the last time has raised by 66.74% from its 52-Week high price while it is -45.13% than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 40.03.
During the trading session, a total of 753061.0 shares were traded which represents a -165.35% decline from the average session volume which is 283800.0 shares. HRZN had ended its last session trading at $6.52. HRZN 52-week low price stands at $4.51 while its 52-week high price is $13.71.
The company in its last quarterly report recorded $0.43 earnings per share which is above the predicted by most analysts. In the second quarter last year, the firm recorded $0.42 earnings per share. Compared to the same quarter last year, the firm’s revenue was up by 34.88%. Horizon Technology Finance Corporation has the potential to record 1.30 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Barclays published a research note on February 27, 2020 where it informed investors and clients that Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is now rated as Overweight. Their price target on the stock stands at $530. Canaccord Genuity also rated REGN as Upgrade on February 26, 2020, with its price target of $550 suggesting that REGN could surge by 9.24% from its current share price. Even though the stock has been trading at $449.53/share, analysts expect it to down by -4.39% to reach $473.52/share. It started the day trading at $458.83 and traded between $427.08 and $429.78 throughout the trading session.
A look at its technical shows that REGN’s 50-day SMA is 413.95 while its 200-day SMA stands at 342.65. The stock has a high of $518.00 for the year while the low is $271.37. The stock, however, witnessed a rise in its short on 03/13/20. Compared to previous close which recorded 2.88 M shorted shares, the short percentage went lower by -11.03%, as 2.56M HRZN shares were shorted. At the moment, only 3.52% of Regeneron Pharmaceuticals Inc. shares were sold short. The company’s P/E ratio currently sits at 23.27, while the P/B ratio is 4.23. The company’s average trading volume currently stands at 1.20M shares, which means that the short-interest ratio is just 2.39 days. Over the past seven days, the company moved, with its shift of -11.39%. Looking further, the stock has raised 14.85% over the past 90 days while it gained 48.35% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The Capital Research & Management Co…. bought more REGN shares, increasing its portfolio by 1.53% during the last quarter. This move now sees The Capital Research & Management Co…. purchasing 125,777 shares in the last quarter, thus it now holds 8,332,424 shares of REGN, with a total valuation of $3,704,345,738. The Vanguard Group, Inc. meanwhile bought more REGN shares in the recently filed quarter, changing its stake to $2,719,049,248 worth of shares.
Similarly, BlackRock Fund Advisors decreased its Regeneron Pharmaceuticals Inc. shares by 2.30% during the recently filed quarter. After selling 4,475,000 shares in the last quarter, the firm now controls -105,383 shares of Regeneron Pharmaceuticals Inc. which are valued at $1,989,450,750. In the same vein, Harris Associates LP decreased its Regeneron Pharmaceuticals Inc. shares by during the most recent reported quarter. The firm bought 225,394 shares during the quarter which decreased its stakes to 4,366,846 shares and is now valued at $1,941,368,726. Following these latest developments, around 20.40% of Regeneron Pharmaceuticals Inc. stocks are owned by institutional investors and hedge funds.